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Abstract
Context: To effectively manage patients with advanced prostate cancer (APC), it is essential to
have accurate, reproducible, and validated methods for detecting and quantifying the burden
of bone and soft tissue metastases and for assessing their response to therapy. Current
standard of care imaging with bone and computed tomography (CT) scans have significant
limitations for the assessment of bone metastases in particular.
Objective: We aimed to undertake a critical comparative review of imaging methods used for
diagnosis and disease monitoring of metastatic APC from the perspective of their availability
and ability to assess disease presence, extent, and response of bone and soft tissue disease.
Evidence acquisition: An expert panel of radiologists, nuclear medicine physicians, and medical
physicists with the greatest experience of imaging in advanced prostate cancer prepared a review
of the practicalities, performance, merits, and limitations of currently available imaging methods.
Evidence synthesis: Meta-analyses showed that positron emission tomography (PET)/CT with
different radiotracersandwhole-bodymagnetic resonance imaging (WB-MRI)aremoreaccurate
for bone lesion detection than CT and bone scans (BSs). At a patient level, the pooled sensitivities
for bone disease by using choline (CH)–PET/CT, WB-MRI, and BS were 91% (95% conﬁdence
interval [CI], 83–96%), 97% (95% CI, 91–99%), and 79% (95% CI, 73–83%), respectively. The pooled
speciﬁcities for bonemetastases detection using CH-PET/CT,WB-MRI, and BS were 99% (95% CI,
93–100%), 95% (95%CI, 90–97%), and82% (95%CI, 78–85%), respectively.Theabilityof PET/CTand
WB-MRI toassess therapeuticbeneﬁts ispromisingbuthasnotbeencomprehensivelyevaluated.
There is variability in the cost, availability, and quality of PET/CT and WB-MRI.
Conclusions: Standardisation of acquisition, interpretation, and reporting of WB-MRI and
PET/CT scans is required to assess the performance of these techniques in clinical trials of
treatment approaches in APC.
Patient summary: PET/CT and whole-bodyMRI scans have the potential to improve detection
and to assess response to treatment of all types of advanced prostate cancer. Consensus
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Advanced prostate cancer (APC) patients who present with
metastatic disease at the time of diagnosis or after failed
attempts at curative therapy almost always respond to
androgen deprivation therapy (ADT). However, ADT initia-
tion inevitably leads to the development of the castration-
resistant disease state, which occurs within 1–3 yr in most
patients [1,2]. More than 80% of patients with metastatic
castrate-resistant prostate cancer (mCRPC) have bone
metastases, which produce significant morbidity and are
associated with increased mortality [3–5]. Data from older
studies suggest that overall survival (OS) is approximately
30–36 mo from the appearance of metastases, with a
median OS of approximately 18 mo once the metastatic
castrate-resistant state is established [6–8]. More contem-
porary data confirm that OS remains poor, approximately
30–42mo [9–11], even with the increased number of active
treatments available for mCRPC. These data emphasise the
continued need for improvements in the diagnosis and
treatment of APC.
With the increasing availability of therapies that prolong
survival for metastatic castrate-naive prostate cancer (PCa)
and mCRPC and the increasing use of prostate-specific
antigen (PSA) testing after definitive therapy, imaging
detection of the metastatic state is occurring for lower
disease burdens. Recent data on patients who developed
metastatic disease indicated that most have bone-only
disease (62%), with bone and soft tissue metastases
occurring in an additional 12% [9]. Soft tissue metastases
occur mostly in lymph nodes outside the true pelvis,
possibly because many patients receive pelvic radiotherapy
for biochemical recurrence (BCR). Visceralmetastases (liver,
lungs, and other sites) occur infrequently at initial relapse
(2%) [9], but prevalence increases with advancing disease
(15–21% in mCRPC) [12,13]. The prevalence of visceral
metastases also increases after multiple lines of treatment
and with the emergence of aggressive histologic variants;
antemortem, visceral disease can be observed in up to half
of the patients [14].
APC patients with bone metastases have a greater risk of
skeletal morbidity, which can impair quality of life (QoL)
[15]. Bone disease causes pain, pathologic fractures,
hypercalcaemia, anaemia, and spinal cord and nerve
compression. Delaying symptoms from bone metastases
as APC progresses is central to therapeutic management
[16]. Treatments for bonemetastases are generally systemic
but often include local radiotherapy and/or surgery; all are
currently given with palliative intent. The treatment of APC
with bone metastases has significant health economic
implications including the costs of systemic therapy
(endocrine therapy, chemotherapy, radioisotope treat-
ments, bisphosphonates, other supportive care medica-
tions); imaging; hospital admissions for the treatment of
fractures, hypercalcaemia, and cord compression; and the
costs of palliative radiotherapy [5,17].
To effectivelymanage patientswithmetastatic disease, it
is essential to have accurate, reproducible, and validated
methods for detecting and assessing response to therapy.These methods include clinical reviews, the use of serum
PSA as a tumour marker, circulating tumour cell counts,
blood and urinary markers of bone health, and imaging
assessments [18,19].
1.1. Need for comprehensive metastatic imaging assessments
Imaging helps define the clinical groups for drug develop-
ment [20] and clarifies the APC state for therapy recom-
mendations [21] because the presence, volume, and
distribution of metastatic disease has profound implica-
tions for the curability of PCa, greatly affecting therapy
choices. At initial staging or in the setting of initial BCR, for
example, the presence of metastatic disease often precludes
the use of curative and local salvage options. The time to
metastasis development in BCR is also highly prognostic,
with a shorter interval to radiographically depicted
metastasis associated with poor OS [22]. The presence
and volume of metastatic skeletal disease is also highly
prognostic, regardless of the imaging method used for
metastatic volume estimation [12,23–26].
Imaging can also identify patientswithmetastatic disease
patterns who have poorer prognosis. Subgroup analysis of
major clinical trials has shown that imaging features
contribute strongly to prognostic models that predict for
survival for docetaxel-treated patients [27]. In mCRPC, the
location of metastases, particularly the presence of visceral
disease and the number of skeletal metastases, are highly
prognostic [13,28–30]. A recent meta-analysis showed
varying OS according to the anatomic location of metastases
in men with mCRPC treated with docetaxel, with increased
lethality for lung and liver metastases compared with bone
and lymph nodal involvement [13].
Patients with poorer prognosis and higher tumour
volumes appear to benefit from intensified combination
treatments [12,31,32]. In the CHAARTED study, ‘‘high
volume’’ disease was defined by the imaging presence of
visceral disease and/or more than four bone metastases
with at least one metastasis beyond vertebral bodies or the
pelvic skeleton [12]. In mCRPC, the presence of visceral or
symptomatic disease is often used as a reason for initiating
chemotherapy in fit patients [21,33].
Patients are deemed to have ‘‘anaplastic features’’ based
on clinical, biochemical, or imaging results. Imaging
features used include exclusively visceral or predominantly
lytic bone metastases, bulky tumour masses, low PSA levels
relative to tumour burden, and short responses to ADT.
Patients defined in this way may benefit more from
combination docetaxel and platinum chemotherapy com-
pared with docetaxel alone [31], although this remains
controversial.
Well-powered clinical studies have shown that that
abiraterone and enzalutamide therapy of asymptomatic or
mildly symptomatic chemotherapy-naive mCRPC patients
can be helpful for delaying clinical decline and death
[10,34]. In this group, lower volume disease such as fewer
than four bone metastases [30] and better performance
status [11,35] seem to indicate improved OS. Note, however,
that the presence of visceral disease and/or large-volume
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such as the alpha particle emitter radium 223 [36].
Finally, the duration of imaging responses is also
reported to be highly prognostic. No response or shorter
durations of response to abiraterone and docetaxel treat-
ments using bone scans (BSs) and the size-based criteria (for
soft tissue disease) are associated with worse OS
[37,38]. These poorer prognosis patients, failing androgen
axis–targeted therapies, may benefit from earlier treatment
with nontargeted survival-prolonging combination thera-
pies such as docetaxel and cabazitaxel while still asymp-
tomatic, although this too remains controversial.
These data, taken together, emphasise the need for
improved precision in evaluating the metastatic status of
APC patients, as baseline imaging characteristics can
influence therapy choices. Furthermore, these data suggest
a need for the detection of metastases when disease load is
lower and formore accurate readouts of therapy benefits (to
detect primary and secondary resistance) to enable
individualised treatment approaches to be investigated.
2. Evidence acquisition
2.1. Search strategy and selection criteria
At the 2015 St. Gallen Advanced Prostate Cancer Consensus
Conference (APCCC), most oncologic experts accepted that
novel imaging techniques (positron emission tomography
[PET]/computed tomography [CT] with different radio-
tracers and whole-body magnetic resonance imaging [WB-
MRI]) are more accurate for lesion detection than conven-
tional imaging with CT and BSs [39]. However, panel
members noted that there was considerable variability in
the cost, availability, and quality of these imaging modali-
ties. Following the APCCC meeting, an expert panel of
radiologists with the largest experience of imaging in APC
convened to review the performance merits and limitations
of currently used imagingmethods.We searched for articles
in PubMed on APC and metastatic disease, focusing on
detection and response assessments between 2000 and
2015. Although the focus was on imaging metastatic PCa,
other tumour types with major malignant bone involve-
ment, including myeloma and breast cancer papers, were
also evaluated for relevant data. All papers identified were
in the English language and were original scientific papers
and review articles. We also searched the references listed
for additional relevant papers and conference proceedings.
As part of the imaging review, guidelines were formulated
on the performance, quality standards, interpretation, and
reporting of WB-MRI for the assessment of APC; see the
accompanying Metastasis Reporting and Data System–
Prostate (MET-RADS-P) publication for the guideline [40].
2.2. Biology of bone disease relevant for imaging
The molecular processes driving PCa cell metastasis to the
bone are beginning to be understood [41–43]. In bone, PCa
cells mostly cause osteoblastic lesions via the secretion of
paracrine factors that stimulate osteoblasts recruitmentand function, thereby leading to excess bone formation.
Osteoclastic activation at the margins allow metastases to
enlarge; the latter mechanism may become dominant in
late-state disease. Tumour-matrix interactions affect the
imaging phenotype; these interactions are summarised in
Supplement 1.
2.3. Current use of imaging in advanced prostate cancer
management
The current use of imaging in APC was surveyed at the
2015 St. Gallen APCCC [39]. An international expert
consensus panel consisting of PCa specialists who were
involved in patient care undertook panel discussions and
voted on predefined questions on the use of imaging. While
continuing to emphasise the use of bone and CT scans, the
APCCC panellists highlighted the need to evaluate newer
imaging modalities for early diagnosis and treatment
monitoring and to assess their impact on patient outcomes.
The APCCC discussions on the current use of imaging in APC
are summarised in Supplement 2.
2.4. Comparison of imaging technologies for metastatic disease
assessments
Radiologic approaches for metastatic evaluations have
specific advantages, including their disease manifesta-
tion–specific depiction ability (ie, ability to separately
assess prostate, bone, nodal, and visceral disease), nonin-
vasive nature, documentation capability, variable ability for
whole-body imaging, resolution flexibility (submillimetre
to subcentimetre), ability to depict physiologic and
molecular processes within and between lesions and
patients, and ability to assess spatial heterogeneity of
disease distribution and response. Comprehensive reviews
of imaging methods for APC can be found in the literature,
and all point out that microscopic metastasis depiction
cannot be comprehensively undertaken by any external
imaging methods [44,45]. In this review, we only comment
on commonly used imaging techniques in the setting of
APC, focusing onmetastasis detection abilities and response
assessment capabilities. In Table 1, we summarised the
advantages and limitations of imaging techniques, focusing
on the partialities of usage.
2.4.1. Bone scans
Currently, BSs are the mainstay of bone metastatic disease
evaluations, including modern extensions such as single-
photon emission CT (SPECT) and SPECT-CT [46]. It is
important to remember that the uptake of technetium Tc
99m bone-binding radiotracers is related to osteoblastic
activity and does not necessarily reflect the full burden of
disease within the marrow space (Fig. 1). Compared with
modern imaging methods such as choline (CH)–PET/CT and
WB-MRI scans, BSs are inferior in terms of lesion detection
ability, as discussed in section 3, ‘‘Evidence synthesis’’
[47,48].
BS evaluations of therapy response are also indirect, with
sensitivity for disease progression only in most cases.
Table 1 – Summary of the advantages and limitations of whole-body imaging methods suited for advanced prostate cancer evaluations
Strengths Weaknesses Opportunities
CT scan  Widely available
 Easily standardised
 Low cost
 Fast acquisition
 Quantitative assessments
(Hounsﬁeld unit)
 Ability to characterise bone disease
into the spectrum between sclerotic
and lytic
 Soft tissue and lytic bone metastasis
detection and response assessments
 Incorporated into clinical practice
and trial guidelines
 Does not directly evaluate malignant bone
disease when soft tissue is absent
 Radiation exposure
 Limited local disease evaluations
 Subcentimetre nodal characterisation
 Cannot visualise inﬁltrative (nonsclerotic)
bone disease
 CT ‘‘ﬂare’’ response
 Inability to diagnose response/progression
in sclerotic bone metastases
 Complementary to PET or whole-body
MRI information
 Sclerotic change in nonsclerotic lesions as
potential response parameter
 Lung metastases detection
 Lytic vs nonlytic bone metastases
subclassiﬁcation
Bone scan  Widely available
 Easily standardised
 Low cost
 Incorporated into clinical practice
and trial guidelines
 Does not directly evaluate malignant bone
disease; reactive osteoblastic uptake only
 Longest examination times
 Pre- and postexamination care precautions
 Radiation exposure to patients and public
due to longer half-life of technetium Tc 99m
 No ability to assess soft tissue disease
 Lower sensitivity and speciﬁcity than
CT/MRI
 Bone scan ﬂare response
 No positive beneﬁt criteria (progression
only)
 Improved test performance by addition of
SPECT/CT capability
Development of bone scan index as
prognostic biomarker
Sodium
ﬂuoride
PET/CT
 High sensitivity and relatively good
speciﬁcity for bone metastases
(CT component adds speciﬁcity)
Medium-length examination times
 Does not directly evaluate malignant bone
disease; reactive osteoblastic uptake only
 Limited tracer availability
 Expensive
 Multiple sources of radiation exposure
(CT scans and radiotracer)
 Some postexamination care precautions
(not burdensome)
 Limited ability to assess soft tissue disease
related to the lower quality of the CT
component; used for attenuation correction
 Flare response phenomenon
 No positive beneﬁt criteria (progression
only)
 Development of NaF tumour volume
index as prognostic biomarker
Choline
PET/CT
 Directly evaluates malignant bone
marrow disease
 High sensitivity and relatively good
speciﬁcity for detection of bone and
soft tissue metastases
 Ability to assess response of bone and
soft tissue disease
 Objective response parameters (SUV)
Medium-length examination times
 Limited tracer availability
 Expensive
 Multiple sources of radiation exposure
(CT scans and 18F-CH radiotracer. less so for
11C-CH due to shorter half-life)
 Some postexamination care precautions
(not burdensome)
 Potential to be inﬂuenced by bone marrow–
stimulating factors
 Inability to accurately assess liver and
urinary lesions
 Development of SUV as a potential
response biomarker
 Development of tumour load as a
prognostic biomarker
Whole-body
MRI
 Directly evaluates malignant bone
marrow disease
 Potential wide availability
Lack of radiation
 Flexible, adaptable imaging (possible
to tailor examinations according to
disease location)
 Ability to detect and assess response
of bone and soft tissue disease
including the prostate, nodes, and
viscera
 Objective response parameters (size,
volume, and ADC measurements)
 Competing demands for MRI resource
 Scanner-dependent performance
 Longer acquisition time
 Susceptible to artefacts
 Subcentimetre nodal and lung metastases
detection and characterisation ability
 Inﬂuenced by bone marrow–stimulating
factors and blood transfusions
 Limited radiologic expertise in some aspects
of image analysis
 Data analysis challenges
 Higher cost (equal to combined bone and CT
scans) and reimbursement challenges
 Radiation-free long-term follow-up
 Surgical planning
 Skeletal event detection (spinal cord
compression, critical fractures)
 ‘‘One stop-shop’’: bone and soft tissue
disease detection and response
assessments
ADC = advanced prostate cancer; CH = choline; CT = computed tomography; MRI = magnetic resonance imaging; PET = positron emission tomography; SPECT =
single-photon emission computed tomography; SUV = speciﬁc uptake values.
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effects is the possibility of a ‘‘flare’’ reaction when BSs are
performed within 8–12 wk of treatment initiation (flare is
defined as the development of new lesions on a first follow-
up scan that actually represent a favourable response to
treatment on longer term observations [20,49]; the
enlargement of previously detected lesions is currently
excluded from the definition of the flare reaction in
pharmaceutical trials). Such flare reactions can occur in
up to 15% of mCRPC patients treated with abiraterone
[37]. These flare reactions can lead to diagnostic confusion
(pseudoprogression vs true progression) and can result in
incorrect management changes [50]. To take into account
the possibility of early flare reactions, the Prostate Cancer
Clinical Trials Working Group (PCWG) suggested that all
patients that have at least two new lesions on the first
follow-up BS require a confirmatory BS to be performed
after >6 wk while treatment is continued [20,51]; BS
progression is documented to have occurred only if two or
more new lesions are seen on the confirmatory BS (2 +2
rule) [20]. This means that management change for primary
therapy resistance cannot occur until after at least 14 wk of
treatment (depending on the reassessment schedule).
Readers should also note that the emergence of two or
more new lesions after the flare period only requires
confirmation on a follow-up scan (ie, new lesions are not
required); this strategy can also result in delays in changing
therapy in the setting of secondary resistance.
We have already noted that BS progression criteria do
not take in consideration increases in extent of preexisting
lesions, relying only on the emergence of new lesions [52],
further limiting the utility of BS to identify disease
progression. Another important point to note is that the
PCWG progression criteria described earlier cannot be
applied to patients with diffuse metastatic bone disease BS
uptake (‘‘superscans’’), as new disease cannot be identified
on the background of diffusely elevated tracer uptake.
It should also be pointed out that the ability of BS to
positively identify response (as opposed to stable or
progressive disease) is also constrained because reductions
of bone activity take a prolonged period of time to occur,
limiting the timeliness of readouts. To date, the rapid
resolution of BS is a phenomenon that is almost never
observed among therapies known to confer survival
benefit; therefore, BS reductions in activity should not be
considered as a positive indicator of response. Rapid
reductions in BS activity were shown in clinical trials of
cabozantinib in APC (Supplementary Fig, 2) [53], but
reductions of BS activity did not predict OS [54].
More recent advances in BS lesion quantification such as
lesion area, the BS index, or lesion number [25,46,55,56] do
not help overcome the limitations of the BS as a tool to
identify therapy benefit. However, as already noted, disease
load depicted on BS is highly prognostic [12,24,25], and
increases in quantitative BS index can be used to identify
disease progression in therapy assessment settings [55,57].
To summarise, the clinical consequences of the limited
performance of BS readouts when assessing response
include (1) inability to diagnose primary and secondarytreatment resistance rapidly, keeping patients on treat-
ments from which they may gain no benefit for longer than
necessary (overtreatment for nonresponding disease), (2)
undertreatment when flare reactions are mistaken for
disease progression in responding patients (pseudoprogres-
sion vs progression confusion), (3) undocumented increases
in tumour burden (increase in extent but not number of
bone lesions) while awaiting the emergence of new lesions
on confirmatory BS (potentially disadvantaging patients
regarding future clinical trials entry). In addition, many
patients with bone superscans cannot be evaluated at all.
For these reasons, in our opinion, the current evidence
points away from the use of BSs for clinical practice when
assessing response in bone disease. However, given the
wide availability of BS and its acceptance in the oncologic
community despite recognised limitations, the BS continues
to be recommended, particularly for clinical trials
[20,21,39,58].
2.4.2. Computed tomography
CT can directly evaluate metastatic disease, providing a
means of detecting and measuring lesions, evaluating
extent of disease involvement, and quantifying response
to treatment of soft tissue disease. Consequently, CT scan
measurements are incorporated into clinical care and
clinical trials for disease detection and response assess-
ment. It must be appreciated that size-based criteria are
severely limited for metastatic nodal disease detection in
PCa [59]. However, there is considerable efficacy using CT-
based size criteria for assessing therapy response of known
soft disease, thus the incorporation of CT measurements
into response assessment systems such the PCWG criteria
and Response Evaluation Criteria In Solid Tumors (RECIST)
[20,60].
CT scans also allow the structure of bone disease to be
evaluated, enabling the primary classification of bone
metastasis on a spectrum from lytic to sclerotic disease.
The biological basis for the range of bone metastasis
manifestations is discussed in detail in Supplement 1. It is
important to note that patients with CT-depicted presence
of predominantly lytic bone metastases associated with
bulky soft tissue disease, including visceral disease (in
patients with low PSA levels relative to tumour burden),
should be considered to have anaplastic features. These
patients may require biopsy with a view to reassessing the
histologic phenotype and to intensive chemotherapy if
anaplastic or neuroendocrine variants are found [31].
Some studies have shown that CT scans are superior to
BSs for detecting lytic bone disease and in differentiating
between sclerotic changes associated with malignancy
versus degenerative disease. Consequently, CT serves as
an aid to improve the test performance of BSs (SPECT/CT)
and sodium fluoride PET scans (NaF-PET/CT). However, test
performance for metastatic detection remains inferior to
WB-MRI and PET/CT scans, especially for nonsclerotic,
nonlytic bone metastases [47], as detailed in section 3,
‘‘Evidence synthesis.’’
It is accepted that CT scans can be used to assess bone
metastasis response to treatment in clinical trials but only
[(Fig._1)TD$FIG]
Fig. 1 – Multiregional whole-body magnetic resonance imaging (WB-MRI) capability. Clinical details: A man aged 74 yr with high-risk prostate cancer
(prostate-specific antigen 37.5 ng/m; Gleason 4 + 4; five of nine cores positive on the left side only). Clinical question: query local and metastatic
staging. (a) Dedicated multiparametric prostate MRI (b value of 750 s/mm2 [b750], apparent diffusion coefficient map, T2-weighted images in the axial
and coronal plane) were undertaken using a 1.5-T scanner. There is a large 4-cm left apical mass bulging the prostatic capsule in the region of the left
neurovascular bundle, indicating T3a disease (arrows). (b) Planar (anterior and posterior views) and single-photon emission computed tomography
(sagittal and axial sections) bone scans showing the presence of a likely metastasis in the upper dorsal spine. Localisation to a specific vertebral body
is difficult. No other lesions were detected. (c) A comprehensive WB-MRI protocol was undertaken using a 3-T scanner (note the higher signal
intensity compared with the 1.5-T scanner images in Fig. 3–5 and Supplementary Fig. 2 and 4). Sagittal short tau inversion recovery (STIR) and
maximum-intensity projection images (anteroposterior projection and right shoulder forward, oblique) all show a metastasis in the T4 vertebral body
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[20,51,60]. However, the presence of measureable soft
tissue occurs in only a minority of bone lesions [61],
rendering many patients with bone disease ineligible for
trial entry because there are no accepted bone tumour
response criteria.
The development of bone sclerosis within metastatic
lesions has been suggested as a method for assessing
response for metastatic breast cancer within the MD
Anderson Cancer Center criteria, provided that bispho-
sphonates are not used [62]. These criteria recognise that
bone structures rarely normalise with effective therapy
and that the development of dense osteosclerosis of a
lytic or mixed lytic/sclerotic lesion can be used as an
indicator of therapy benefit because increased osteoblas-
tic activity occurs as a healing response. However, no CT
density thresholds have been established for distinguish-
ing inactive bone metastases from active sclerotic
metastases, although emerging data suggest that a
well-defined bone lesion with homogenous increased
CT density (>800–1000 Hounsfield units) can be rela-
tively inactive when judged on CH-PET/CT scans [63]. The
CT flare phenomenon, defined as the emergence of a new
bone lesion or a transformational change of an ill-defined
sclerotic lesion into a dense, well-marginated bone lesion,
has been described in 8% of APC patients and has been
successfully treated [64]. The development of new
osteosclerotic lesions should not be classified as progres-
sion on its own unless there is other evidence of disease
progression.
Taking the above discussion into considerations, we
suggest that bone disease progression on CT can be
identified by the unequivocal presence of new or enlarging
soft tissue disease associated with bone lesions or by the
rapid disappearance of sclerotic disease due to replacement
by visible lytic disease. New sclerotic lesions by themselves
do not constitute progression, particularly when dense or
well defined. However, the emergence of new woven bone
(milky or irregular appearance with ill-defined margins) in
previously normal-appearing regions maybe considered as
progression in the presence of consistent MRI/PET-depicted
abnormalities and/or clinicallyworsening disease and in the
absence of antiosteoclastic treatments (Fig. 2). We assert
that early response of bone metastases on CT scans in the
absence of extraosseous soft tissue disease cannot be
identified but may be seen late when normal trabecular
bone is restored.
2.4.3. Positron emission tomography
Two PET radiotracers are widely used for imaging APC: the
bone-seeking tracer fluorine F 18 (18F)–NaF, which, like
99mTc-MDP, acts as a more efficient marker of osteoblastic(arrow). The lower signal in centre of the lesion on the STIR image is consisten
T3. The primary tumour at the left prostatic apex is also visible (arrows). (d) (l
column) T1-weighted fat-fraction images confirm the presence of the metasta
row; arrow), and multiple smaller lesions are in the left posterior iliac bone (b
weighted b900 images of the L5 and iliac bone lesions.
ADC = apparent diffusion coefficient; AP = anteroposterior; b750 = b value of 75
recovery; TW1 = T1 weighted; T2W = T2 weighted.action; and themetabolic tracer carbon 11 (11C)/18F–CH, the
uptake of which is partially related to membrane phospho-
lipid synthesis [65,66]. There are many other PET tracers,
such as fluorodihydrotesterone (directed to the androgen
receptor [AR]), gallium- and fluoride-labelled prostate-
specific membrane antigen (PSMA), and F-fluciclovine
(amino acid transportation; approved by the US Food and
Drug Administration in 2016), that have variable geograph-
ic availability and for which assessment of clinical utility for
disease detection and response in APC is ongoing [67]. The
more commonly used general oncology radiotracer fluor-
odeoxyglucose (FDG-PET/CT) is not often used in the
evaluation of APC because of its low sensitivity for disease
detection [68]. However, it has been reported that in APC
patients with FDG-avid metastases, the amount and extent
of FDG-avid disease inversely correlate with survival [61].
CH-PET has potential advantages in displaying changes
in metabolic activity that may occur prior to changes in CT-
depicted morphology [63]. CH-PET/CT scans are superior to
BSs and CT scans for detecting bone disease, with
performance equivalent to WB-MRI scans [48]. CH-PET/
CT performs poorly in the liver because there is high
background hepatic uptake, limiting potential use for later
stages of mCRPC, when there is an increased prevalence of
metastatic liver disease [14]. In addition, 18F-CH–PET/CT
performs poorly in the evaluation of the urinary tract due to
urinary excretion (not seen with 11C-CH). In contrast, CH-
PET/CT performs better than WB-MRI in the assessment of
lymph nodes [48] (Supplementary Fig. 3), although there
are limitations in detectingmicroscopic disease in normally
sized nodes at low serum PSA levels (<0.5–1.0 ng/ml in
prostatectomy patients) [69]. The ability of CH-PET/CT to
assess response has not been systematically evaluated, but
a few small studies have shown changes in disease extent
and specific uptake values in response to treatment
[23,63,70] (Fig. 3). It should also be noted that the flare
phenomenon (false increases in fluorocholine PET tracer
uptake) can also be observed in responding bone lesion
early after starting abiraterone [70].
Preliminary data suggested that PSMA-targeted N-(N-
[(S)-1,3-dicarboxypropyl]carbamoyl)-4-18F-fluorobenzyl-L-
cysteine (18F-DCFBC) PET/CT has improved performance
compared with CT and BS for disease detection [71]. Early
data also suggested that the more frequently used gallium
Ga 68 PSMA radiotracers have greater sensitivity for disease
detection than CH-PET/CT in patientswith BCR, especially at
low PSA values, although test performance remains
dependent on PSA levels [72–74]. The improved perfor-
mance of PSMA-PET/CT compared with CH-PET/CT is
possibly caused by lowered background activity in the
bones and liver [73,75]. The ability of PSMA-PET/CT to
evaluate therapy response has not been systematicallyt with mineralisation. There is osteoporotic loss of vertebral height at
eft column) B value of 900 s/mm2 (b900) diffusion-weighted and (right
sis at T3 (top row; arrow). Further metastases are seen at L5 (middle
ottom row; arrows). Note the lower lesion contrast on the diffusion-
0 s/mm2; b900 = b value of 900 s/mm2; STIR = short tau inversion
[(Fig._2)TD$FIG]
Fig. 2 – Bone disease progression criteria. A man aged 74 yr with metastatic castrate-resistant prostate cancer was treated with abiraterone. Increasing
symptoms with nausea and bone pain were accompanied by a rise in serum prostate-specific antigen. Computed tomography scans before and during
treatment. Software straightening and vertebral body labelling of the lumbar spine was undertaken for illustration purposes. There is evidence of
disease progression due to the presence of new woven bone (milky or irregular appearance with ill-defined margins) in previously normally appearing
regions in the lumbar spine and sacrum with loss of height in several vertebrae.
PSA = prostate-specific antigen.
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PSMA expression is dependent on the AR status of PCa cells,
and the way in which AR-directed treatments alter PSMA-
PET/CT test sensitivity remains largely unexplored [76,77].
2.4.4. Magnetic resonance imaging
MRI can also directly evaluate metastatic disease, providing
a means of detecting and measuring lesions, evaluating the
extent of disease involvement, and quantifying response to
treatment of both soft tissue and bone marrow disease.
Consequently, MRI scan measurements are incorporated
into clinical care and clinical trials for disease detection and
response assessment, often as alternatives to CT scans. CT
detection is superior for lung metastasis, but MRI performs
better in detecting liver lesions. As with CT, size-based
criteria severely limit metastatic nodal disease detection in
PCa [59].The key advantage of MRI is that bone marrow disease is
directly evaluated. MRI sequences can be designed to be
sensitive to different aspects of themarrow, such asmarrow
water and fat (using proton density–weighted, T1-weighted
[T1W], T2-weighted [T2W], and short t inversion recovery
[STIR] sequences), the cellularity of the bone marrow
(diffusion-weighted [DW] MRI), vascularity (dynamic
contrast-enhanced MRI), trabecular bone (ultrashort echo
time MRI and susceptibility weighted MRI), and bone
marrow fat:water ratio (Dixon MRI, magnetic resonance
spectroscopy). Importantly, techniques can be combined
within the same examination to enable both morphologic
and functional (including quantitative) assessments that
can be repeated as often as required, as there is no radiation
exposure penalty. Another advantage of MRI is the ability
to perform disease-tailored multiregional studies focused
on the bones, lymph nodes, viscera, and prostate gland
[(Fig._3)TD$FIG]
Fig. 3 – Choline positron emission tomography (PET) to monitor response to chemotherapy. A man aged 57 yr with metastatic castrate-resistant
prostate cancer. Fluorocholine PET scans (frontal projection, inverted scale). Note normal high radiotracer uptake in liver, kidneys, urinary bladder,
pancreas, small bowel, salivary glands, and pituitary fossa. (Left panel) Status after abiraterone and docetaxel (prostate-specific antigen [PSA] 5.2 ng/
ml) showing mediastinal (horizontal arrow) and retroperitoneal (slanting arrow). (Middle panel) After six cycles of cabazitaxel chemotherapy (PSA
3.2 ng/ml), the patient showed a good response with residual abnormalities. (Right panel) Extensive relapsed disease on follow-up (PSA 133 ng/ml)
with extensive subdiaphragmatic nodal relapse together with left supraclavicular nodal disease (vertical down arrow). New metastasis in the left
upper femur. Note fading of background bone marrow due to cell kill effects of chemotherapy.
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detection and response assessment can be performed
in<1 h; practical WB-MRI sequence protocols can be found
in the accompanying MET-RADS-P standards publication
[40].
2.4.4.1. Morphologic magnetic resonance imaging scans. Morpho-
logic T1W, T2W, and STIR images can be easily acquired on
all MRI scanners without exception, and radiologic exper-
tise for their interpretation is widely available [78,79]. Mor-
phologic sequences are key for the confident detection of
new metastases until the time when diffuse disease occurs,
after which the detection of disease reactivation becomes
problematic. Morphologic criteria for bone disease progres-
sion and response are well described in the literature
[78]. Small studies in metastatic breast cancer have
described morphologic MRI bone marrow changes in
response to treatment [80,81]. A study evaluating
109 MRI studies in advanced breast cancer found that it
was possible to accurately predict progression in 79% of
cases and stable disease in 75% of cases, but MRI could not
predict regression of disease due to the limitations of
morphologic sequences [81]. Specific clinical data on the
use of morphologic MRI in the routine assessment of
metastatic bone disease response in APC are lacking
[82]. Tombal et al noted that there was an opportunity to
measure bone disease using morphologic MRI sequences
(disease that would otherwise be considered unmeasurable
by RECIST) and, in so doing, to potentially double the
proportion of APC patients who could be entered into
clinical trials [83]. This suggestion of RECIST-like criteria forbone disease assessment has not been widely taken up nor
validated in clinical trials.
Morphologic MRI sequences that assess bone marrow
response have a number of limitations, including arrested
resolution of abnormalities despite effective therapy (the
residual scar phenomenon, presumed to be due to bone
sclerosis,marrow fibrosis, or tumour necrosis) [81]. Another
limitation is the problem of evaluating disease activity on a
background of previously treated disease (ie, progression
can be documented only by the emergence of new disease
on previously uninvolved marrow). A T1W image pseudo-
progression, the flare phenomenon, can also occur because
of intense bone marrow oedema following tumour cell kill
and inflammation. T1W flare is more likely to be associated
with chemotherapy use and, locally, after radiation
treatment, but its frequency is undocumented.
2.4.4.2. Diffusion-weighted images. The disease detection and
response assessment performance of WB-MRI is enhanced
by adding DW sequences [84–86], which also help to
overcome some of the limitations ofmorphologic sequences,
described earlier. DW images depict the per-pixel averages
(ie, at millimetre scale) of microscopic tissuewatermobility.
Modified fat-suppressed T2W sequences are adapted by
adding sets of magnetisation gradients that, depending on
their timing and magnitude (denoted as the b value, in
seconds per square millimetre), induce sensitisation to
tissue water diffusion in the resulting images. The water
diffusivity can be calculated (apparent diffusion coefficient
[ADC] value, in square micrometres per second) [87] and
reflects the freedom of water movement. At the cellular
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properties such as cellular density, cellular arrangements,
vascularity and extracellular space, tissue viscosity, and
tortuosity. A negative correlation between cellular density
and ADC value is usually found in soft tissue tumours
[88]. Similarity, negative correlations between PCa tumour
proliferation and ADC values have been recorded [88,89].
Two kinds of images are produced from diffusion
sequences: a set of qualitative DW images (one for each
b value) and one quantitative ADC map, both of which need
to be assessed. High–b value images are often reconstructed
(using maximum-intensity projections) to appear ‘‘PET-
like,’’ wherein the distribution of malignant disease appears
bright (or dark on inverted grey-scale images) (Fig. 1 and
3–5; Supplementary Figs. 2–4). On whole-body DW
imaging (WB-DWI), infiltrative skeletal metastases appear
as focal or diffuse areas of high signal intensity on high–b
value images on a background of the lower signal intensity
of the normal bone marrow [86,90,91].
It is important to emphasise thatmetastasis depiction by
WB-DWI should always be correlated with appearances on
complementary anatomic sequences to avoid false results
[92,93]. Correlations of signal intensity on high–b value
images with ADC measurements is especially important for
bone lesion characterisation. ADC values of normal marrow
are lower than those of metastases due to the presence of
marrow fat, with a cut-off value between 600 and 700 mm2/
s [94–96] when b values between 50 and 900 s/mm2 are
used. Recommended cut-off values between normal mar-
row and tumour are set out in detail in the MET-RADS-P
standards document [40].
Recently, Perez-Lopez et al. described a semiautomated
segmentation tool to derive tumour volume estimates from
high–b value images and to obtain global tumour ADC
histograms. Tumour volume measurements from WB-DWI
undertaken in this way have been shown to be prognostic in
APC [26]. Whole-body tumour volumes and ADC histo-
grams can also be used to assess disease response to therapy
[97], as illustrated in Fig. 4 and Supplementary Figure 2 and
4. The process of tumour cell lysis and apoptosis disrupts
cellular membranes, increasing tissue water diffusivity and
thus reducing the signal intensity on high–b value images
and increasing ADC values [98–100].
3. Evidence synthesis
3.1. Metastasis detection
Several meta-analyses have shown that the performance of
WB-MRI for bone and soft tissue disease detection is
comparable to that of FDG-PET/CT, both being significantly
more accurate than BS and CT inmajority of solid cancers on
per-patient and per-lesion bases [47,48,86,101]. Yang et al
showed that for all metastatic disease detection on a per-
patient basis, the pooled sensitivity estimates for FDG-PET/
CT, CT,WB-MRI, and BSwere 89.7%, 72.9%, 90.6%, and 86.0%,
respectively. The pooled specificity estimates for FDG-PET/
CT, CT,WB-MRI, and BSwere 96.8%, 94.8%, 95.4%, and 81.4%,
respectively [47].The improved test performance of WB-MRI applies to
skeletal assessments in APC specifically when CH-PET/CT is
used as the comparator technique. Shen et al conducted a
meta-analysis of 27 studies in APC and showed that MRI
was superior to CH-PET/CT and BS for metastasis detection
on a per-patient basis. On a per-patient basis, the pooled
sensitivities for bone disease using CH-PET/CT, WB-MRI,
and BS were 91% [95% confidence interval [CI], 83–96], 97%
(95% CI, 91–99), 79% (95% CI, 73–83), respectively. The
pooled specificities for bone metastasis detection using CH-
PET/CT, WB-MRI, and BS were 99% (95% CI, 93–100), 95%
(95% CI, 90–97), and 82% (95% CI, 78–85), respectively.
[48]. In a per-lesion analysis, CH-PET/CT had a higher
diagnostic odds ratio that exceeded both BS and bone SPECT
for detecting bone metastases.
A recent meta-analysis underscored the usefulness of
DWI as a method that improves the detection of bone
metastases. Liu et al. [86] evaluated 32 studies with
1507 patients and showed pooled sensitivity, specificity,
and area under the curve for DWI of 95% (95% CI, 90–97),
92% (95% CI, 88–95), and 0.98, respectively, on a per-patient
basis and 91% (95% CI, 87–94), 94% (95% CI, 90–96), and
0.97, respectively, on a per-lesion basis.
When evaluating the results of the above meta-analyses
and, indeed, in all studies reporting test performance,
readers should note that intrinsic verification biases are
particularly prevalent at lesion-level analyses because it is
simply not possible to obtain histopathology for every bone
lesion detected, for ethical and practical clinical reasons
[102,103]. Consequently, most studies use combinations of
imaging methods and/or follow-up as the standards of
reference. Furthermore, as with all external imaging
methods, microscopic metastasis depiction cannot be
comprehensively undertaken.
3.2. Response assessment
Both preclinical and small-scale clinical studies indicate
that DWI can be useful for the assessment of therapy
response in malignant bone marrow disease in PCa.
Preclinical mouse model studies of osseous PCa have
shown increases in ADC values with therapeutic success.
A mouse model of PCa bone metastases, for example,
demonstrated increased ADC values in response to chemo-
therapy [104]. ADC increases were also noted in PCa bone
metastases models treated with combination docetaxel and
anti-CCL2 therapy [105] and with cabozantinib [106].
Few systematic studies have been done in PCa patients
with bone disease in response assessment settings [94,107];
there are many case series in the context of methodology
development [97,100] and assessments of bone disease
response when involvement occurs by other malignancies.
The study of Reischauer et al, for example, found that mean
ADC values of lesions increased significantly after hormonal
therapy, in keeping with successful responses gauged by
PSA declines [107]. Slight ADC elevations were also noted in
nonresponders, but these increases were <20%, whereas
ADC increases in responders were of greater magnitude.
Interestingly, therewas also noticeable spatial heterogeneity
[(Fig._4)TD$FIG]
Fig. 4 – Monitoring therapy response to docetaxel chemotherapy. Clinical details: A man aged 76 yr with metastatic castrate-resistant prostate cancer
treated with docetaxel chemotherapy. Examinations were obtained at baseline (prostate-specific antigen [PSA] 427 ng/ml) and after three cycles (PSA
301 ng/ml) and six cycles (PSA 136 ng/ml). Clinical question: extent of tumour response. Whole-body magnetic resonance imaging (MRI) scans were
performed using a 1.5-T scanner. (a) Diffusion-weighted MRI with a b value of 900 s/mm2 (b900) and maximum-intensity projection (inverted grey
scale, anterior projections) at the three time points (TPs; baseline [TP1] and after three [TP2] and six [TP3] cycles of docetaxel). Extensive bone disease
was detected as decreasing in extent and intensity over the three TPs; residual bone disease can still be seen at TP3. Note the emergence of liver
metastases (arrows) at TP2 that remain at TP3. (b) T2-weighted fat-saturation (T2W-FS) and T1-weighted (T1W) MRI at the three TPs. Very little change
was observed in the T2W-FS images, but increased bone fat can be seen in the lower thoracic and lumbar spine on T1W images at TP3 (arrows); this is
consistent with some response to treatment. (c) Segmented whole-body b900 MRI images at the three TPs, using signal normalisation across TPs and
identical signal intensity thresholds. Corresponding apparent diffusion coefficient (ADC) histograms for the three TPs, in each case compared with TP1.
The x-axis is the ADC value (in micrometres per second), and the y-axis is the relative frequency. TP1 (blue): 1142 ml of tumour is segmented. The
histogram is unimodal with high kurtosis (mean ADC 712 mm2/s, kurtosis 10.1). TP2 (orange): 500 ml of tumour is segmented. The histogram is still
unimodal but moves to the right and decreases kurtosis (mean ADC 1107 mm2/s, kurtosis 4.1). This finding is in keeping with therapy response. TP3
(green): 360 ml of tumour is segmented. The histogram is now bimodal with the left peak corresponding in value to TP1, and the right peak remains
at the value seen at TP2. The failure in the histogram to move further to the right at TP3, together with findings on the other images (liver metastases,
persistent abnormalities on morphologic sequences), indicates nonresponse to treatment (secondary resistance). Docetaxel treatment was terminated,
and enzalutamide treatment commenced. Image analysis was performed using prototype software (syngo.via Frontier MR Total Tumor Load; Siemens
Healthcare, Erlangen, Germany).
TW1 = T1 weighted; T2W-FS = T2-weighted fat saturation; TP = time point.
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having greater increases in ADC values, and variations
between metastases in individual patients. Similar findings
of increased ADC values in bone disease have been described
for multiple myeloma, myeloproliferative diseases, breast
cancers, and primary bone tumours with a variety of
treatments, indicating that bone tumour ADC increases
with successful treatment is a generic finding [108–117].
This matches similar observations made in other organ
systems [118].3.3. Recommendations
Our review indicates that both WB-MRI and CH-PET/CT
are suitable for wide deployment in disease detection
settings, given their test performance, potential wide
availability, and multiorgan evaluation capabilities. Suffi-
cient data now indicate thatWB-MRI has better accuracy for
detecting bone metastases than BS to confidently recom-
mend use for bone metastasis detection. Although further
data, including comparative multimodal studies, are
[(Fig._5)TD$FIG]
Fig. 5 – Monitoring soft tissue disease therapy response. Clinical details: A man aged 68 yr with metastatic castrate-resistant prostate cancer after
docetaxel and abiraterone, treated with mitoxantrone and prednisone. Examinations were obtained at baseline (prostate-specific antigen [PSA] 259 ng/
ml) and after 12 wk of treatment (PSA 6093 ng/ml). Clinical question: query evidence of tumour response. whole-body magnetic resonance imaging
scans were performed using a 1.5-T scanner. (Left panels) Diffusion-weighted images with a b value of 900 s/mm2 (b900) and inverted maximum-
intensity projection (anterior projections). (Right panels) Planar bone scans (anterior view) at the corresponding time points. Extensive liver disease
(horizontal white arrows) is visible, increasing in extent over 12 wk, indicating disease progression. There is lymph nodal disease progression (black
arrowheads) within the abdomen and pelvis, including new nodal disease in the left supraclavicular fossa. There was no change in the bone deposits
on the diffusion or bone scans (black arrows). Note increased lower limb lymph oedema visible on both scan types. Further active treatment was
terminated.
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recent European Organisation for Research and Treatment
of Cancer position paper also concluded that MRI offers a
good ‘‘one size fits all’’ solution for patients who do not have
substantial nonbone disease to assess therapy effectiveness
[82].
The St. Gallen APCCC panellists correctly asked whether
earlier detection of metastatic disease using highly sensitive
imaging methods like WB-MRI and PET/CT will have
significant clinical benefits in terms of significant impacts
on QoL and OS [39]. Similarly, they asked whether earlier
detection of treatment failure or primary resistance by more
sensitive methods, and subsequent modifications in life
prolonging treatments, would have benefits in terms of
maintaining QoL and improving OS. These questions are
worth investigating because there are indications that
earlier, timely detection and treatment initiation in oligo-
metastatic APC may be beneficial [119]. Some approved
treatments are more suited to lower volume disease (local
treatments such as surgery and targeted radiation, treat-
ments targeting the androgen axis, and systemic immuno-
therapy). Furthermore, some treatments may work better
when used in asymptomatic or minimally symptomatic
patients with better performance status [30,34,35,120].
Emerging guidelines are beginning to recommend prospec-
tive screening for metastatic disease in asymptomatic PCa
patients, with a view to earlier initiation of treatments and
clinical trial entry in oligometastatic disease, and in thesetting of nonmetastatic CRPC [20,121,122]. To date,
however, there are few data on the benefits of treatment
modifications based on the earlier detection of treatment
failure or primary resistance and on the negative QoL effects
of continued treatments with ineffective drugs [39].
The cost ofWB-MRI and PET/CT are often highlighted as a
hindrance for clinical adoption in some health systems.
However, costs are dependent on the availability of these
technologies. Generally, within Europe, the cost of WB-MRI
is comparable to the combined costs of CT and BS for
the detection of bone and nodal metastases (Table 1)
[123,124]. Furthermore, because WB-MRI costs are largely
determined by in-room table time, which is rapidly
decreasing as MRI machine performance improves, we
can expect to see WB-MRI scan times decrease.
There is a recognised need for standardisation of
acquisition, interpretation, and reporting of WB-MRI
[39]. The MET-RADS-P imaging recommendations have
been developed to address these needs [40]. The WB-MRI
methods proposed can be adapted for use in advanced
metastatic breast cancer (MET-RADS-B) and for multiple
myeloma (MET-RADS-MM); in passing, readers should note
that WB-MRI is already recommended as the first-line tool
for investigation in myeloma [125]. The proposed MET-
RADS-P system is suitable for clinical practice and can be
incorporated into clinical trials, generating measures that
can serve as new biomarkers, which in turn will require
independent validation [20].
E U RO P E AN URO LOG Y F O CU S 3 ( 2 0 1 7 ) 2 2 3 – 2 3 9 235Initially, we suggest thatWB-MRI be evaluated in clinical
trials that assess the effects of treatments that are
anticipated or known to kill tumour cells, such as those
targeting the androgen axis, cytotoxic chemotherapy, and
radium 223. More novel trials could include targeted
radiotherapy for oligometastases, PARP inhibitors, and
immunotherapies. In these studies, WB-MRI should be
compared with current criteria (eg, changes in PSA, other
biochemical markers, circulating tumour cells) and corre-
lated to QoL measures, rates of skeletal events, and
progression-free survival, so as to justify the inclusion of
WB-MRI in future studies. Comparative clinical studies of
test performance against established and emerging PET
radiotracers would also be of interest. The latter are
prerequisites for the successful introduction of WB-MRI
into longer term follow-up studies that prospectively
collect appropriate metadata that would allow objective
assessments of whether WB-MRI is effective in directing
patient care and supporting drug development.
4. Conclusions
Imaging techniques including WB-MRI and PET/CT scans
have the potential to address the unmet need for robust
imaging methods that allow tumour detection and therapy
evaluations in APC. WB-MRI can detect bone metastases
with higher sensitivity than BSs and with performance at
least comparable to that of CH-PET/CT. Early and more
accurate detection of tumour burden may have positive
therapy implications. Importantly, WB-MRI provides clear-
er categorisation of bone metastasis response, unlike BSs,
which only identify disease progression; more accurate
assessments of therapy response (including heterogeneity
of response) could further aid the rational development of
targeted therapies.
There is a clear need for standardisation of WB-MRI and
PET/CT technologies. The proposed MET-RADS-P system
[40] enables complete characterisation of APC state using
WB-MRI not only at the start of treatments but also over
time as the disease evolves. MET-RADS-P allows the
categorisation of patients with specific patterns of disease
for clinical trial stratification. MET-RADS-P also enables the
evaluation of the benefits of continuing therapy when there
are signs that the disease is progressing (discordant
responses). Clearly, WB-MRI is not at the point where it
can support regulatory approvals of new therapeutic
approaches. It is anticipated that as evidence accrues from
clinical trials, more specific recommendations and/or
algorithms incorporating WB-MRI and PET/CT will emerge.
We recommend that WB-MRI and the MET-RADS-P system
now be evaluated in clinical trials to assess the impact on
the clinical management of APC.
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